Dapagliflozin Tablet
Product Images NDC 67296-2334

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Dapagliflozin (NDC 67296-2334). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

546 (Dapagliflozin 10mg 30s)

Label for Dapagliflozin Tablets USP 10 mg oral tablets, manufactured by Macleods Pharmaceuticals Ltd. The label shows the product is made for Macleods Pharma USA, Inc. It includes storage instructions, a barcode, and notes that the package contains 30 tablets. The label also advises dispensing the accompanying medication guide.*

FDA Label Image

546 (Dapagliflozin 10mg 90s)

Dapagliflozin Tablets USP 10 mg oral tablets packaging label from Macleods Pharma USA. The label states 90 tablets per container and includes storage instructions, dosage reference, manufacturing details by Macleods Pharmaceuticals Ltd, India, and a website for medication guide access.*

FDA Label Image

585 (Dapagliflozin 5mg 30s)

Packaging label for Dapagliflozin Tablets, USP 5 mg, oral tablet dosage form. The label shows the drug name, strength of 5 mg, package contains 30 tablets, and is manufactured by Macleods Pharmaceuticals Ltd, India for Macleods Pharma USA, Inc. Storage instructions and usage warnings are also included.*

FDA Label Image

879 (Dapagliflozin 5mg 90s)

This is a packaging label for Dapagliflozin Tablets USP, 5 mg strength. The label shows 90 tablets dispensed by Macleods Pharma USA, manufactured by Macleods Pharmaceuticals Ltd. in India. It provides storage instructions, dosage note referring to prescribing information, and warnings about product integrity and keeping out of children's reach.*

FDA Label Image

505 (Dapagliflozin Fig 1)

This is a scatter plot graph showing 24-hour urinary glucose excretion (CFB) versus dapagliflozin dose (mg) on a logarithmic scale. The graph compares observed values and fitted lines for healthy subjects and subjects with type 2 diabetes mellitus (T2DM), illustrating the relationship between dapagliflozin dose and urinary glucose levels.*

FDA Label Image

658 (Dapagliflozin Fig 2)

A line graph showing the adjusted mean percentage change in HbA1c from baseline over 24 study weeks for three treatments: dapagliflozin 10 mg plus metformin, dapagliflozin 10 mg alone, and metformin alone. The x-axis represents study weeks, and the y-axis displays HbA1c change percentage. A secondary plot on the right shows Week 24 values with 95% confidence intervals.*

FDA Label Image

575 (Dapagliflozin Figure 3)

A line graph showing adjusted mean percentage change in HbA1c from baseline over 24 study weeks comparing placebo plus metformin against dapagliflozin 10 mg plus metformin. The graph includes data points at multiple weeks and a separate bar graph on the right for Week 24 (LOCF) with 95% confidence intervals. Dapagliflozin 10 mg plus metformin shows a greater reduction in HbA1c compared to placebo plus metformin.*

FDA Label Image

505 (Dapagliflozin Figure 4)

A line graph comparing the percentage of patients with events over months from randomization between dapagliflozin and placebo groups. The y-axis represents patients with event (%) and the x-axis shows months from randomization up to 60 months. The dapagliflozin group shows a lower event rate over time compared to placebo. Patient counts at risk are listed below the x-axis for both groups.*

FDA Label Image

505 (Dapagliflozin Figure 5)

A line graph comparing the percentage of patients with an event over time between dapagliflozin and placebo groups. The x-axis shows months from randomization up to about 60, and the y-axis shows percent of patients with events, ranging from 0 to 4.5%. Two lines are plotted: a solid line for dapagliflozin and a dashed line for placebo, with dapagliflozin showing a consistently lower event rate than placebo over time. Below the graph is a table listing numbers of patients at risk at various time points for both groups.*

FDA Label Image

556 (Dapagliflozin Stru)

Chemical structure of dapagliflozin showing the molecular arrangement, including a chlorophenyl group, ether linkage, and glucose moiety in the structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.